|
| Reference | Study drugs | Study population and design | Study duration | Findings |
|
| Cacciatore et al. [98] | Enalapril 20 mg/day versus zofenopril 30 mg/day, | 36 patients with newly diagnosed mild hypertension, randomized trial | 5 years | ↑ EPC count
No difference between groups
↓ intima media thickness |
|
| Sun et al. [99] | Perindopril 4 mg/day versus placebo | 68 patients with acute myocardial infarction and T2DM | 28 days after PCI | ↑ EPC count
↑ VEGF
↑ SDF-1α
↑ LVF
↓CV mortality in the perindopril group |
|
| Min et al. [100] | Ramipril 5 mg/day | 36 nondiabetic patients with acute myocardial infarction | 4 weeks | ↑ EPC count 1.5-fold after 1 week, 2.5-fold after 4 weeks
↑ EPC proliferation, migration, and adhesion |
|
| Cangiano et al. [101] | Perindopril 10 mg/day versus valsartan 320 m/day | Patients with acute coronary syndromes
16 receiving perindopril
17 receiving valsartan
20 healthy controls | 30 days | ↑ EPC mobilization, ↑ VEGF in the perindopril group
No effects found for valsartan |
|
| Porto et al. [102] | Ramipril 5 mg/day versus telmisartan 80 mg/day | 42 patients with acute coronary syndrome, randomized trial | 20 days after PCI | ↑ EPC count in both groups Telmisartan had a more profound anti-inflammatory effect |
|
| Pelliccia et al. [103] | Telmisartan 40 mg/day versus placebo | 40 normotensive patients with CAD, randomized trial | 4 weeks | ↑ EPC count
↑ FMD |
|
| Bahlmann et al. [95] | Olmesartan 40 mg/day versus placebo, double-blind RCT
Irbesartan 300 mg/day, open trial | 18 patients with T2DM randomized to olmesartan or placebo
20 patients with T2DM receiving irbesartan | 12 weeks | ↑ EPC count with both olmesartan and irbesartan |
|
| Tan et al. [104] | Losartan 100 mg/day | | | ↑ EPC count
↑ FMD |
|
| Suzuki et al. [105] | Losartan 50 mg/day versus trichlormethiazide 4 mg/day | 36 patients with hypertension randomized to losartan or trichlormethiazide
Control group: 18 normotensive patients | 4 weeks | ↑ EPC count with losartan
Hypertensive patients had a lower EPC count in comparison to normotensive patients |
|
| Kampoli et al. [106] | Pioglitazone (15 m/day) versus perindopril (4 mg/day) | 50 patients with T2DM, randomized trial | 1 month | No effect on EPC |
|
| Sugiura et al. [96] | Nifedipine SR 20 mg/day versus placebo | 37 hypertensive patients with stage I hypertension, randomized trial | 4 weeks | ↑ EPC count
↑ EPC differentiation migration, resistance to oxidative stress
↑ FMD |
|
|
de Ciuceis et al. [97] | Barnidipine 20 mg/day versus hydrochlorothiazide 25 mg/day | 29 hypertensive patients with mild essential hypertension, randomized trial | 6 months | ↑ EPC count with barnidipine
No difference in RR reduction observed between drugs |
|
